In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center.Here are some of the key articles we discussed:1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”. https://pubmed.ncbi.nlm.nih.gov/36989488/ 2. CAR-HEMATOTOX score: https://pubmed.ncbi.nlm.nih.gov/34166502/ 3. “How I treat cytopenias after CAR T-cell therapy”. https://pubmed.ncbi.nlm.nih.gov/36800563/ 4. Immune Effector Cell-Associated HLH-Like Syndrome (ASTCT): https://pubmed.ncbi.nlm.nih.gov/36906275/ 5. ASTCT consensus grading for CRS and ICANS: https://pubmed.ncbi.nlm.nih.gov/30592986/6. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: https://pubmed.ncbi.nlm.nih.gov/35696759/ 7. Modified EASIX score for predicting CRS and neurotoxicity: https://pubmed.ncbi.nlm.nih.gov/34432870/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related